Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer

BACKGROUND: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment. However, the incidence and risk of fatal adverse events (FAEs) following PD-1/PD-L1 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Zhao, Hong, Zhao, Jiaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005982/
https://www.ncbi.nlm.nih.gov/pubmed/32082425
http://dx.doi.org/10.1177/1758835919895753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005982/
https://www.ncbi.nlm.nih.gov/pubmed/32082425
http://dx.doi.org/10.1177/1758835919895753

Ejemplares similares